Oral Ketamine's Quiet Revolution: A Pill to Treat Depression at Home?

MUNICH, Germany – July 07, 2026 – The landscape of mental healthcare is perpetually searching for its next breakthrough, particularly for the estimated 100 million people globally grappling with treatment-resistant depression (TRD). Today, a significant development emerged with the publication of clinical trial data from HMNC Brain Health in the peer-reviewed JAMA Network Open. The German neuroscience company’s candidate, Ketabon (KET01), an oral prolonged-release ketamine formulation, demonstrated a capacity to deliver antidepressant effects with what the company describes as minimal dissociative and cardiovascular side effects—the very issues that have tethered existing ketamine therapies to clinical settings. While the data presents a compelling case for a paradigm shift toward at-home treatment, it also contains nuances that warrant a closer look.

Deconstructing the Data: Promise and Caveats

The publication details two studies that put KET01 to the test. A Phase 1 trial directly compared a 240 mg oral dose of KET01 against an 84 mg dose of the market-leading intranasal esketamine, Spravato. The results were stark. While Spravato induced clinically significant dissociation in nearly all participants, only one of 26 subjects on KET01 experienced the same. The statistical difference was profound (p<0.00000000001), underscoring the prolonged-release formulation's ability to smooth out the drug's psychoactive impact. This is achieved by delivering a lower, slower peak of ketamine in the bloodstream—around 6 to 7 hours, compared to 30 minutes for its intranasal competitor—which fundamentally alters the patient experience and, crucially, the safety profile.

Building on this favorable tolerability, a Phase 2 trial evaluated KET01 in 122 outpatients with TRD over three weeks. Here, the drug's potential efficacy came into view. Patients receiving the 240 mg daily dose showed rapid reductions in depressive symptoms, measured by the Montgomery–Åsberg Depression Rating Scale (MADRS). Statistically significant improvements over placebo were noted as early as Day 4 and Day 7, signaling a potent and fast-acting antidepressant effect. For a patient population in desperate need of relief, this rapid onset is a powerful signal.

However, the trial's primary endpoint—the change in MADRS score at Day 21—was not met. The company attributes this to a substantial improvement in the placebo group, a common and confounding variable in psychiatric drug trials. While the 240 mg KET01 group showed a robust -13.15 point drop in MADRS scores, it wasn't enough to achieve statistical significance over the placebo arm at the final measure. Dr. Maximilian Doebler, HMNC's Chief Business Officer, acknowledged they were “a bit unlucky” with the endpoint but stressed the importance of the early separation between the groups. This mixed result is the central tension of the KET01 story so far: a revolutionary safety profile and rapid action paired with a primary endpoint that will need to be definitively hit in larger, more expensive Phase 3 trials.

The At-Home Paradigm Shift

Despite the Day 21 results, the true disruptive potential of KET01 lies not just in its efficacy but in its delivery model. The current generation of ketamine-based treatments, like Spravato, mandates administration in a certified medical setting, followed by hours of monitoring. This creates significant logistical and financial burdens for patients and healthcare systems, limiting access and scalability. HMNC’s strategic objective is to shatter this paradigm.

By engineering out the severe dissociative and cardiovascular side effects, KET01 is being positioned as the first ketamine therapy safe enough for at-home use after an initial supervised dose. This would represent a tectonic shift in TRD treatment, transforming a high-intensity clinical procedure into a manageable, take-home prescription. The implications for patient access, convenience, and overall healthcare costs are immense.

Investors are clearly buying into this vision. In June, HMNC announced a $50 million first closing of a Series B financing round, led by the German drugmaker MEDICE. The deal goes beyond capital, with MEDICE also licensing the European commercialization rights for KET01. This provides HMNC not only with the funds to advance its pipeline but also a strategic partner to navigate the European market. The financing will fuel a planned Phase 2b study in 2027 and other Phase 3-enabling activities, pushing KET01 closer to its 2028 market entry target.

Navigating the Regulatory Gauntlet

Innovation, especially involving a controlled substance, is always met with intense regulatory scrutiny. The path to approving an at-home ketamine therapy is fraught with challenges. Regulators at the FDA and EMA will require an exceptionally high bar of evidence to be cleared, focusing on the potential for misuse, diversion, and patient safety outside the controlled environment of a clinic.

HMNC's entire strategy hinges on its ability to prove that KET01's unique pharmacokinetic profile makes it fundamentally different and safer. The company's argument is that the slow-release mechanism and lower peak concentration not only mitigate the acute psychedelic effects that necessitate clinical supervision but also may reduce the drug's abuse potential. The upcoming Phase 2b study, which will test a less frequent dosing schedule, and the subsequent global Phase 3 program will be the ultimate test of this hypothesis.

These trials must be meticulously designed to collect long-term safety data and demonstrate the effectiveness of any proposed risk mitigation strategies. HMNC has indicated it is in discussions with the FDA on these very points, signaling an awareness of the steep climb ahead. The company's success will depend not only on demonstrating efficacy but on building an unassailable safety case that convinces regulators, doctors, and patients that the benefits of at-home access outweigh the inherent risks of a controlled substance. The industry will be watching closely, as a positive outcome for KET01 could pave the way for a new class of more accessible psychiatric medicines.